18 / 33
Efficacy of 2nd line
chemo post IO?
mPFS2 on
second-line
therapy
21.5
(
87.5% platinum-based)
versus
8.5
(
94.4% IO)
Rina Hui
et al, COSA 2017
0
3
6
9
1 2
1 5
1 8
2 1
2 4
2 7
3 0
3 3
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
T im e , m o n th s
P F S 2 , %
P e m b ro 1 5 4
1 3 4
1 1 7
1 0 8
9 6
8 0
7 3
6 4
3 8
1 2
3
0
C h e m o 1 5 1
1 2 2
1 0 0
6 4
5 7
4 2
3 5
2 5
1 3
7
2
0
N o . a t ris k
67.6%
41.8%
49.7%
19.0%
Events, n
HR (95% CI)
Pembrolizumab
73
0.46 (0.34
–0.62)
Chemotherapy
113
Median (95% CI)
21.5 mo (14.8 mo–NR)
8.5 mo (7.2–11.4 mo)